Testosterone Lawsuit News: Bernstein Liebhard LLP Notes European Review of Heart Risks Potentially Associated with Low Testosterone Therapy
New York, New York (PRWEB) April 15, 2014 -- As testosterone lawsuits (http://www.testosteronelawsuitcenter.com/) involving AndroGel and other low testosterone therapies continue to move forward in U.S. courts, Bernstein Liebhard LLP notes that European regulators have launched a new review of heart risks potentially associated with this class of medications. According to a notice issued on April 11, 2014, by the European Medicines Agency (EMA), the review was prompted by the release of research which suggested that the use of testosterone increases the risk heart attack in men over 65-years-old, as well as in younger men with pre-existing heart disease. The notice pointed out that the study was just the most recent to suggest that men who use testosterone therapy may face a higher risk of heart problems compared to men who did not receive the drugs.*
“The EMA is the latest entity to raise concerns about the heart risks that may be associated with this class of medications. In the U.S., a growing number of testosterone treatments lawsuits have been filed on behalf of men who allegedly experienced life-threatening heart problems due to these medications,” says Bernstein Liebhard LLP, a nationwide law firm representing the victims of defective drugs and medical devices. The Firm is currently offering free legal reviews to anyone who may have suffered serious heart attacks, strokes, deep vein thrombosis or pulmonary embolism, allegedly due to the use of prescription testosterone therapies.
Testosterone Treatment Lawsuits
Testosterone drugs are sold in many forms, including pills, injectables, and topical creams and gels. According to the U.S. Food & Drug Administration (FDA), brand-name medications in this class include:**
• AndroGel
• Androderm
• Axiron
• Bio-T-Gel
• Delatestryl
• Depo-Testosterone
• Fortesta
• Striant
• Testopel
On January 31, 2014, the FDA also announced that it had launched a review of heart risks associated with low testosterone therapies. The FDA’s notification cited the same research that prompted the EMA’s review.
According to court documents, dozens of testosterone treatment lawsuits have been filed in U.S. courts since the FDA announced its review. On March 28th, plaintiffs who have filed AndroGel lawsuits asked the U.S. Judicial Panel on Multidistrict Litigation to transfer all federally-filed cases to the U.S. District Court, Northern District of Illinois for coordinated pretrial proceedings. Among other things, their brief noted that more than 30 AndroGel lawsuits were pending in federal courts around the country, the majority of which had been filed in the Northern District of Illinois. (In Re: AndroGel Product Liability Litigation, No. 36, JPML)
In addition to AndroGel, court filings show that a number of testosterone lawsuits have been filed against the manufacturer of Testim. These include two claims that were filed last month in the U.S. District Court, Eastern District of Pennsylvania. (Case Nos. 140301684 and 140302537). Those cases followed the filing of a Testim lawsuit in February in the U.S. District Court, Northern District of California in February. (Case No. No. 14-278).
Men who used low testosterone therapies may be entitled to compensation if they experienced serious heart problems during treatment. To learn more about filing a testosterone lawsuit, please visit Bernstein Liebhard LLP’s website. Free, no-obligation legal consultations can be obtained by calling 800-511-5092.
*ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/referrals/Testosterone-containing_medicines/human_referral_prac_000037.jsp&mid=WC0b01ac05805c516f, EMA, April 11, 2014
**accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&SearchType=BasicSearch&searchTerm=testosterone&Search_Button=Submit
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the Plaintiffs’ Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since the list was first published in 2003.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
800-511-5092
ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Contact Information:
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info (at) consumerinjurylawyers (dot) com
http://www.testosteronelawsuitcenter.com/
https://plus.google.com/115936073311125306742?rel=author
Felecia L. Stern, Testosterone Lawsuit Information Center, http://www.testosteronelawsuitcenter.com/, +1 800-511-5092, [email protected]
Share this article